BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22847344)

  • 1. Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma.
    McClanahan F; Hielscher T; Rieger M; Hensel M; Bentz M; Schmidt-Wolf I; Käbisch A; Salwender H; Dürk H; Staiger H; Mandel T; Neben K; Hillengass J; Leo E; Krämer A; Ho AD; Witzens-Harig M
    Am J Hematol; 2012 Oct; 87(10):E68-71. PubMed ID: 22847344
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost-effectiveness of extended adjuvant rituximab for US patients aged 65-70 years with follicular lymphoma in second remission.
    Hayslip JW; Simpson KN
    Clin Lymphoma Myeloma; 2008 Jun; 8(3):166-70. PubMed ID: 18650180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-hyper-CVAD versus R-CHOP/cytarabine with high-dose therapy and autologous haematopoietic stem cell support in fit patients with mantle cell lymphoma: 20 years of single-center experience.
    Widmer F; Balabanov S; Soldini D; Samaras P; Gerber B; Manz MG; Goede JS
    Ann Hematol; 2018 Feb; 97(2):277-287. PubMed ID: 29147847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab in combination with multiagent chemotherapy for pediatric follicular lymphoma.
    Kumar R; Galardy PJ; Dogan A; Rodriguez V; Khan SP
    Pediatr Blood Cancer; 2011 Aug; 57(2):317-20. PubMed ID: 21462303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016.
    Press OW; Unger JM; Rimsza LM; Friedberg JW; LeBlanc M; Czuczman MS; Kaminski M; Braziel RM; Spier C; Gopal AK; Maloney DG; Cheson BD; Dakhil SR; Miller TP; Fisher RI
    J Clin Oncol; 2013 Jan; 31(3):314-20. PubMed ID: 23233710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
    Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
    Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
    Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
    Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative dose intensity of R-CHOP therapy and patient outcomes in advanced follicular lymphoma.
    Konishi T; Kanemasa Y; Sasaki Y; Okuya T; Yamaguchi T; Funasaka C; Shimoyama T; Omuro Y
    Hematol Oncol; 2019 Aug; 37(3):303-307. PubMed ID: 30933366
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP.
    Harjunpää A; Taskinen M; Nykter M; Karjalainen-Lindsberg ML; Nyman H; Monni O; Hemmer S; Yli-Harja O; Hautaniemi S; Meri S; Leppä S
    Br J Haematol; 2006 Oct; 135(1):33-42. PubMed ID: 16925574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Hornberger JC; Best JH
    Cancer; 2005 Apr; 103(8):1644-51. PubMed ID: 15756658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of older patients with mantle-cell lymphoma.
    Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
    N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
    Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
    Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatal visceral varicella-zoster infection following rituximab and chemotherapy treatment in a patient with follicular lymphoma.
    Bermúdez A; Marco F; Conde E; Mazo E; Recio M; Zubizarreta A
    Haematologica; 2000 Aug; 85(8):894-5. PubMed ID: 10942955
    [No Abstract]   [Full Text] [Related]  

  • 16. Cost-effectiveness of the addition of rituximab to CHOP chemotherapy in first-line treatment for diffuse large B-cell lymphoma in a population-based observational cohort in British Columbia, Canada.
    Johnston KM; Marra CA; Connors JM; Najafzadeh M; Sehn L; Peacock SJ
    Value Health; 2010; 13(6):703-11. PubMed ID: 20561333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma.
    Zinzani PL; Pulsoni A; Perrotti A; Soverini S; Zaja F; De Renzo A; Storti S; Lauta VM; Guardigni L; Gentilini P; Tucci A; Molinari AL; Gobbi M; Falini B; Fattori PP; Ciccone F; Alinari L; Martelli M; Pileri S; Tura S; Baccarani M
    J Clin Oncol; 2004 Jul; 22(13):2654-61. PubMed ID: 15159414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab (anti-CD20 monoclonal antibody) as consolidation of first-line CHOP chemotherapy in patients with follicular lymphoma: a phase II study.
    Jäeger G; Neumeister P; Brezinschek R; Höfler G; Quehenberger F; Linkesch W; Sill H
    Eur J Haematol; 2002 Jul; 69(1):21-6. PubMed ID: 12270058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.